Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

The use of prophylactic anticonvulsants in patients with brain tumours: a clinical practice guideline.

BIBLIOGRAPHIC SOURCE(S)

  • Perry J, Zinman L, Laperriere N, Chambers A, Lloyd N, Spithoff K, Neuro-oncology Disease Site Group. The use of prophylactic anticonvulsants in patients with brain tumours: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2006 Oct 11. 23 p. (Evidence-based series; no. 9-4). [16 references]

GUIDELINE STATUS

BRIEF SUMMARY CONTENT

 RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

  • The routine use of postoperative anticonvulsants is not recommended in seizure-naïve patients with newly diagnosed primary or secondary brain tumours, especially in light of a significant risk of serious adverse effects and problematic drug interactions. This recommendation is in agreement with the American Academy of Neurology (AAN) practice parameter.
  • There is insufficient evidence to support or refute the use of anticonvulsants in the perioperative period for patients with brain tumours who have never had a seizure.
  • There is very little evidence to guide treatment for patients who are already on anticonvulsants but have never had a seizure. There is insufficient evidence to recommend whether or not anticonvulsants should be tapered in this situation and therefore treatment must be individualized.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The recommendations are supported by one evidence-based practice guideline, five randomized controlled trials, one systematic review, and one retrospective review.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Perry J, Zinman L, Laperriere N, Chambers A, Lloyd N, Spithoff K, Neuro-oncology Disease Site Group. The use of prophylactic anticonvulsants in patients with brain tumours: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2006 Oct 11. 23 p. (Evidence-based series; no. 9-4). [16 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2006 Oct

GUIDELINE DEVELOPER(S)

Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]

GUIDELINE DEVELOPER COMMENT

The Program in Evidence-based Care (PEBC) is a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.

SOURCE(S) OF FUNDING

Cancer Care Ontario
Ontario Ministry of Health and Long-Term Care

GUIDELINE COMMITTEE

Neuro-oncology Disease Site Group

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

The members of the Neuro-oncology Disease Site Group (DSG) were asked to disclose potential conflicts of interest relating to the topic of this systematic review and meta-analysis. No conflicts were declared.

GUIDELINE STATUS

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on March 28, 2008.

COPYRIGHT STATEMENT

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo